Protocol Library

Single peptide protocols

Individual compounds, each with its own record of what published research reports and what is still unverified.

Educational reference only. Peptides Made Clear does not provide medical advice, dosing recommendations or administration guidance. Values shown are what published sources or reviewed records report, never a suggestion for personal use.

Single peptide records

Showing 53 of 58 protocol records.

Cinematic 3D visualization of the stomach, pancreas, liver and abdominal tissue with illuminated metabolic pathways.

5-Amino-1MQ

5-amino-1-methylquinolinium

Single peptideSource verified

Evidence: Animal research
Route: Subcutaneous (animal research), Oral (community-reported)
Schedule: Once to three times daily in animal studies
Vials: 10 mg

View protocol7 citations

Cinematic 3D visualization of the human brain with glowing synaptic activity and neural pathways.

Adamax

Single peptideSource verified

Evidence: Laboratory research
Route: Sold as an intranasal or injectable research chemical.
Schedule: Not established.
Vials: No verified presentation recorded

View protocol1 citation

Cinematic 3D macro cross-section of skin layers, collagen fibers and a hair follicle.

AHK-Cu

Single peptideSource verified

Evidence: Animal research
Route: Research vials and cosmetic-formulation products are sold. No approved or studied human route exists.
Schedule: Not established. No human study exists.
Vials: 50 mg

View protocol2 citations

AICAR

Acadesine (5-aminoimidazole-4-carboxamide ribonucleotide)

Single peptideSource verified

Evidence: Animal research
Route: Human trials used intravenous infusion in hospital settings. Research vials are sold online; no approved or studied human vial route exists.
Schedule: Not established for any non-hospital use. No human study of vial-format use exists.
Vials: 50 mg

View protocol4 citations

AOD-9604

Single peptideSource verified

Evidence: Animal research
Route: Studied orally in the obesity programme. Injectable forms sold online are unapproved and were not the subject of the pivotal trials.
Schedule: Trials used daily oral administration over 12 to 24 weeks.
Vials: No verified presentation recorded

View protocol1 citation

Cinematic 3D visualization of skeletal muscle fiber bundles and tendons with illuminated recovery pathways.

ARA-290

ARA-290 (cibinetide), an 11-amino-acid innate repair receptor agonist derived from erythropoietin helix B

Single peptideSource verified

Evidence: Early human research
Route: Subcutaneous injection in the published phase 2 human trials; intravenous in some earlier work
Schedule: Phase 2 trials used daily subcutaneous administration over defined study periods of roughly four to twenty-eight days depending on the protocol.
Vials: 4 mg, 16 mg

View protocol6 citations

BPC-157

Pentadecapeptide BPC 157 (GEPPPGKPADDAGLV)

Single peptideSource verified

Evidence: Early human research
Route: Oral tablet and intravenous infusion in the published human studies; intraperitoneal and intragastric in the rodent literature
Schedule: Not established for any human indication. The registered human studies were dose-escalation safety designs, not schedules intended for repeated use.
Vials: 5 mg, 10 mg

View protocol6 citations

Cagrilintide

Single peptideSource verified

Evidence: Controlled human trials
Route: Subcutaneous injection, in every published human trial
Schedule: Once weekly in the published trial programme
Vials: 5 mg, 10 mg

View protocol6 citations

Cinematic 3D visualization of the human heart and vascular network with illuminated circulation.

Cardiogen

Single peptideSource verified

Evidence: Laboratory research
Route: Marketed as an oral capsule and, in some listings, as an injectable preparation. No approved route exists.
Schedule: Not established. Vendor listings describe courses of daily use, but these come from sellers rather than from a regulator or a controlled trial.
Vials: No verified presentation recorded

View protocol1 citation

Cinematic 3D visualization of a knee joint showing cartilage, tendons and ligaments with illuminated repair pathways.

Cartalax

Single peptideSource verified

Evidence: Laboratory research
Route: Marketed as an oral capsule and, in some listings, as an injectable preparation. No approved route exists.
Schedule: Not established. Vendor listings describe courses of daily use, but these come from sellers rather than from a regulator or a controlled trial.
Vials: No verified presentation recorded

View protocol1 citation

Cerebrolysin

Single peptideSource verified

Evidence: Human observational or case reports
Route: Intravenous infusion or intramuscular injection, administered in clinical settings in countries where it is registered.
Schedule: Registered use involves daily courses over a defined number of days rather than continuous use.
Vials: No verified presentation recorded

View protocol1 citation

CJC-1295 with DAC

CJC-1295 with DAC (drug affinity complex), also known as CJC-1295-DAC and in development as ConjuChem CJC-1295

Single peptideSource verified

Evidence: Human observational or case reports
Route: Subcutaneous injection in the published human trials
Schedule: Published trial work used single or infrequent subcutaneous administration, consistent with a multi-day half-life. No approved regimen exists.
Vials: 2 mg, 5 mg

View protocol6 citations

CJC-1295 without DAC

CJC-1295 without DAC, commonly called modified GRF(1-29) or tetrasubstituted GHRH(1-29)

Single peptideSource verified

Evidence: Laboratory research
Route: Subcutaneous injection is the route described in non-clinical use. No approved or trial-established route exists for this molecule.
Schedule: Not established. No approved label or dedicated human trial defines a frequency.
Vials: 2 mg, 5 mg

View protocol6 citations

Cortagen

Single peptideSource verified

Evidence: Laboratory research
Route: Marketed as an oral capsule and, in some listings, as an injectable preparation. No approved route exists.
Schedule: Not established. Vendor listings describe courses of daily use, but these come from sellers rather than from a regulator or a controlled trial.
Vials: No verified presentation recorded

View protocol1 citation

DSIP

Single peptideSource verified

Evidence: Animal research
Route: Studied by intravenous and other parenteral routes in older research. Sold as an injectable research chemical.
Schedule: Not established. Older studies used single or short-course administration.
Vials: No verified presentation recorded

View protocol1 citation

Epithalon

Single peptideSource verified

Evidence: Laboratory research
Route: Sold as a lyophilised research chemical for injection. No approved route.
Schedule: Not established. Vendor listings describe short repeated courses; this is seller convention, not evidence.
Vials: No verified presentation recorded

View protocol1 citation

Follistatin-344

Single peptideSource verified

Evidence: Laboratory research
Route: Research reagent; no approved human route.
Schedule: Not established.
Vials: No verified presentation recorded

View protocol1 citation

Cinematic 3D macro visualization of a mitochondrion inside a cell with glowing energy transfer.

FOXO4

Single peptideSource verified

Evidence: Laboratory research
Route: Preclinical injection in animals. No approved human route.
Schedule: Not established in humans. Mouse work used intermittent administration.
Vials: No verified presentation recorded

View protocol1 citation

GHK-Cu

GHK-Cu, copper tripeptide-1 (glycyl-L-histidyl-L-lysine copper complex)

Single peptideSource verified

Evidence: Controlled human trials
Route: Topical in the human evidence; subcutaneous and intraperitoneal in rodent models only
Schedule: Topical cosmetic studies applied a cream formulation on a daily schedule over a defined study period. No human schedule exists for injected GHK-Cu.
Vials: 50 mg, 100 mg

View protocol6 citations

Glutathione

Single peptideSource verified

Evidence: Animal research
Route: Oral supplementation is common. Intravenous and intramuscular preparations are marketed by clinics but are not FDA-approved.
Schedule: Supplement labels commonly describe daily oral use. No approved injectable schedule exists.
Vials: No verified presentation recorded

View protocol1 citation

Cinematic 3D visualization of the endocrine system with illuminated pituitary, thyroid, adrenal and pancreatic regions.

HCG

Single peptideSource verified

Evidence: Controlled human trials
Route: Intramuscular or subcutaneous injection of a reconstituted lyophilised powder, prescribed and supervised by a clinician.
Schedule: Approved products define injection schedules per indication, commonly several times weekly for male hypogonadism.
Vials: No verified presentation recorded

View protocol1 citation

Humanin

Single peptideSource verified

Evidence: Animal research
Route: Research studies used injection in animals. No approved human route.
Schedule: Not established in humans.
Vials: No verified presentation recorded

View protocol1 citation

IGF-1 LR3

Single peptideSource verified

Evidence: Laboratory research
Route: Sold as a lyophilised research reagent. No approved human route exists.
Schedule: Not established. No controlled human study defines a schedule.
Vials: No verified presentation recorded

View protocol1 citation

Ipamorelin

Ipamorelin (NNC 26-0161), Aib-His-D-2-Nal-D-Phe-Lys-NH2

Single peptideSource verified

Evidence: Human observational or case reports
Route: Human trials used intravenous administration. Subcutaneous use is the common non-clinical route and is not supported by an approval or a route-matched efficacy trial we could verify.
Schedule: Not established. No approved regimen exists. Published clinical work used short investigational intravenous dosing in a hospital setting.
Vials: 2 mg, 5 mg, 10 mg

View protocol6 citations

Kisspeptin-10

Single peptideSource verified

Evidence: Human observational or case reports
Route: Investigational studies have used intravenous infusion or subcutaneous injection in controlled settings.
Schedule: Study-specific; infusion protocols and single injections have both been used in research.
Vials: No verified presentation recorded

View protocol1 citation

Cinematic 3D visualization of the stomach, intestines, liver and pancreas with warmly illuminated gut pathways.

KPV

KPV (Lys-Pro-Val), C-terminal tripeptide of alpha-MSH

Single peptideSource verified

Evidence: Animal research
Route: Oral and intraperitoneal in mouse models, including a nanoparticle-delivered oral formulation. No human route has been studied.
Schedule: Not established. No human schedule exists, and animal experiments used study-specific regimens.
Vials: 5 mg, 10 mg

View protocol6 citations

L-Carnitine

Single peptideSource verified

Evidence: Early human research
Route: Oral supplementation, or intravenous levocarnitine in approved deficiency indications. Compounded intramuscular injections sold for fat loss are not approved.
Schedule: Approved deficiency treatment schedules are defined in labelling and set by a clinician.
Vials: No verified presentation recorded

View protocol1 citation

Cinematic 3D visualization of immune cells signaling within tissue in teal and green light.

LL-37

LL-37, human cathelicidin antimicrobial peptide (hCAP18 C-terminal fragment)

Single peptideSource verified

Evidence: Early human research
Route: Topical application in the human wound studies. Intravenous and other systemic routes are not established.
Schedule: Topical wound studies applied the peptide on study-defined schedules. No systemic human schedule is established.
Vials: 5 mg, 10 mg

View protocol6 citations

Melanotan I

Single peptideSource verified

Evidence: Controlled human trials
Route: Subcutaneous bioresorbable implant inserted by a healthcare professional in approved use.
Schedule: Implants are placed at approximately two-month intervals during periods of light exposure, per the approved label.
Vials: No verified presentation recorded

View protocol1 citation

Melanotan II

Single peptideSource verified

Evidence: Laboratory research
Route: Sold as a lyophilised research chemical for subcutaneous injection. No approved route.
Schedule: Not established. No controlled human study defines a schedule.
Vials: No verified presentation recorded

View protocol1 citation

MOTS-c

Single peptideSource verified

Evidence: Animal research
Route: Animal studies used injection. No approved human route.
Schedule: Not established in humans.
Vials: No verified presentation recorded

View protocol1 citation

Neutral molecular research illustration for NAD+.

NAD+

Single peptideSource verified

Evidence: Animal research
Route: Intravenous infusion in clinic settings, or oral precursor supplements. No approved injectable NAD+ product exists.
Schedule: Clinic infusion schedules are set by the provider and have no approved basis. Precursor trials used daily oral administration.
Vials: No verified presentation recorded

View protocol1 citation

Oxytocin Acetate

Single peptideSource verified

Evidence: Controlled human trials
Route: Approved use is intravenous infusion in a hospital. Intranasal oxytocin is used in research studies only.
Schedule: Titrated by infusion in obstetric care. Research studies of intranasal oxytocin typically used single administrations before a task.
Vials: No verified presentation recorded

View protocol1 citation

P21

Single peptideSource verified

Evidence: Laboratory research
Route: Preclinical animal studies used injection. No human route exists.
Schedule: Not established in humans.
Vials: No verified presentation recorded

View protocol1 citation

PE-22-28

Single peptideSource verified

Evidence: Laboratory research
Route: Preclinical injection in animals. No human route.
Schedule: Not established in humans.
Vials: No verified presentation recorded

View protocol1 citation

Pinealon

Single peptideSource verified

Evidence: Laboratory research
Route: Marketed as an oral capsule and, in some listings, as an injectable preparation. No approved route exists.
Schedule: Not established. Vendor listings describe courses of daily use, but these come from sellers rather than from a regulator or a controlled trial.
Vials: No verified presentation recorded

View protocol1 citation

Cinematic 3D visualization of DNA strands and mitochondria in a luminous cellular network.

PNC-27

Single peptideSource verified

Evidence: Laboratory research
Route: Preclinical injection in animals. No approved human route.
Schedule: Not established in humans.
Vials: No verified presentation recorded

View protocol1 citation

PT-141

Single peptideSource verified

Evidence: Controlled human trials
Route: Subcutaneous injection in the abdomen or thigh, per the approved label
Schedule: As needed, at least 45 minutes before anticipated sexual activity, with the label limiting use to one dose in 24 hours and no more than eight doses per month.
Vials: No verified presentation recorded

View protocol2 citations

Retatrutide

Single peptideSource verified

Evidence: Controlled human trials
Route: Subcutaneous injection, in every published human trial
Schedule: Once weekly in the published phase 2 and phase 3 programmes
Vials: 5 mg, 10 mg, 15 mg, 20 mg, 30 mg

View protocol6 citations

Selank

Single peptideSource verified

Evidence: Animal research
Route: Intranasal solution in registered use; also sold as injectable research material.
Schedule: Registered use describes short daily courses.
Vials: No verified presentation recorded

View protocol1 citation

Semaglutide

Single peptideSource verified

Evidence: Controlled human trials
Route: Subcutaneous injection once weekly (Ozempic, Wegovy) and oral tablet once daily (Rybelsus)
Schedule: Once weekly subcutaneously in the approved injectable presentations; once daily orally in the approved tablet presentation
Vials: 2 mg, 5 mg, 10 mg, 15 mg

View protocol6 citations

Semax

Single peptideSource verified

Evidence: Animal research
Route: Intranasal solution in registered Russian use; also sold as injectable research material.
Schedule: Registered use describes short daily courses rather than continuous use.
Vials: No verified presentation recorded

View protocol1 citation

Sermorelin

Sermorelin acetate, GHRH(1-29) amide

Single peptideSource verified

Evidence: Controlled human trials
Route: Subcutaneous injection, the route in the former approved labelling
Schedule: Former approved labelling described once-daily subcutaneous injection at bedtime in paediatric growth hormone deficiency.
Vials: 2 mg, 5 mg, 6 mg

View protocol6 citations

SLU-PP-332

Single peptideSource verified

Evidence: Laboratory research
Route: Preclinical injection in mice. No human route established.
Schedule: Not established in humans.
Vials: No verified presentation recorded

View protocol1 citation

SNAP-8

Single peptideSource verified

Evidence: Animal research
Route: Topical, as part of a finished cosmetic formulation. No injectable route is established or documented.
Schedule: Determined by the finished product, typically once or twice daily application as directed on the label. There is no separate peptide regimen.
Vials: No verified presentation recorded

View protocol1 citation

SS-31

Single peptideSource verified

Evidence: Early human research
Route: Subcutaneous injection in the clinical programme, with ophthalmic formulations studied separately.
Schedule: Clinical trials used daily subcutaneous administration over defined study periods.
Vials: No verified presentation recorded

View protocol1 citation

TB-500

TB-500 (vendor name for synthetic thymosin beta-4 fragments)

Single peptideSource verified

Evidence: Animal research
Route: Topical and intravenous in the published human studies of full-length thymosin beta-4. No published human study of the TB-500 fragment by any route was located.
Schedule: Not established for TB-500. Published human schedules belong to full-length thymosin beta-4 in topical and intravenous trials and cannot be transferred to a different molecule and route.
Vials: 5 mg, 10 mg

View protocol6 citations

Tesamorelin

Tesamorelin (EGRIFTA, EGRIFTA WR), a stabilised 44-amino-acid GHRH analogue

Single peptideSource verified

Evidence: Controlled human trials
Route: Subcutaneous injection into the abdomen, per the approved label
Schedule: Once daily subcutaneous injection, continuously, per the approved label.
Vials: 1 mg, 5 mg, 10 mg

View protocol6 citations

Thymalin

Thymalin, a low-molecular-weight polypeptide complex extracted from calf thymus

Single peptideSource verified

Evidence: Human observational or case reports
Route: Intramuscular injection of a reconstituted lyophilisate, per Russian product labelling
Schedule: Russian product labelling describes daily intramuscular administration for short courses of roughly three to ten days, with courses sometimes repeated periodically.
Vials: 10 mg

View protocol6 citations

Thymosin Alpha-1

Thymosin alpha-1 (thymalfasin), a synthetic 28-amino-acid acetylated thymic peptide

Single peptideSource verified

Evidence: Controlled human trials
Route: Subcutaneous injection in essentially all approved use and trial protocols
Schedule: Chronic hepatitis regimens used twice-weekly subcutaneous administration over months. Sepsis trials used short courses of daily or twice-daily administration over five to seven days.
Vials: 1.6 mg, 5 mg, 10 mg

View protocol6 citations

Tirzepatide

Single peptideSource verified

Evidence: Controlled human trials
Route: Subcutaneous injection once weekly
Schedule: Once weekly subcutaneous administration in every approved presentation and published trial
Vials: 5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 60 mg

View protocol6 citations

VIP

Vasoactive intestinal peptide (VIP); aviptadil is the synthetic pharmaceutical form

Single peptideSource verified

Evidence: Controlled human trials
Route: Intravenous infusion in critical COVID-19 trials; inhaled and nebulised in pulmonary hypertension and sarcoidosis studies
Schedule: Intravenous trial protocols used continuous infusion over hours per day for a few days. Inhaled studies used single or short-course administration. These are acute hospital protocols, not ongoing schedules.
Vials: No verified presentation recorded

View protocol6 citations

Vitamin B12

Single peptideSource verified

Evidence: Controlled human trials
Route: Oral supplementation, intramuscular injection, or nasal spray, depending on the product and the cause of deficiency.
Schedule: Defined by the treating clinician; loading and maintenance schedules for deficiency are set out in approved labelling.
Vials: No verified presentation recorded

View protocol1 citation